rosiglitazone has been researched along with thiazoline-2-thione in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunskill, NJ; Chana, RS | 1 |
| Beck-Nielsen, H; Home, PD; Jones, NP; Kahn, SE; Noronha, D; Viberti, G | 1 |
1 trial(s) available for rosiglitazone and thiazoline-2-thione
| Article | Year |
|---|---|
Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials.
Topics: Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Neoplasms; Rosiglitazone; Sulfonylurea Compounds; Thiazolidinediones; Thiazolidines; Treatment Outcome | 2010 |
1 other study(ies) available for rosiglitazone and thiazoline-2-thione
| Article | Year |
|---|---|
Thiazolidinediones inhibit albumin uptake by proximal tubular cells through a mechanism independent of peroxisome proliferator activated receptor gamma.
Topics: Albumins; Anilides; Animals; Cells, Cultured; Cholesterol; Chromans; Farnesol; Kidney Tubules, Proximal; Ligands; Mevalonic Acid; Opossums; Polyisoprenyl Phosphates; PPAR gamma; Rosiglitazone; Thiazoles; Thiazolidinediones; Thiazolidines; Troglitazone | 2006 |